Siyu Feng

Siyu Feng, PhD, serves as a Senior Scientist at BridgeBio Oncology Therapeutics since May 2024, leading the cell biology team in the discovery and development of novel small molecule inhibitors for the "PI3Ka:RAS Breaker" program. Previously, Siyu held a similar role at BridgeBio starting in August 2021 and worked as a Postdoctoral Research Fellow at Genentech from August 2019 to August 2021, focusing on gene engineering and functional genomics to target oncogenic drivers. Notable achievements include participation as a finalist in the Merck Biopharma Innovation Cup in June 2019 and significant research contributions during graduate studies at the University of California, San Francisco, where Siyu investigated cancer signaling mechanisms and mentored undergraduate students. Siyu holds a Ph.D. in Bioengineering and Biomedical Engineering from the University of California, San Francisco, and the University of California, Berkeley, and a Bachelor's degree in Bioengineering from Beihang University, complemented by international experiences in tissue engineering and biomedical engineering.